Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M: A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion
hepatitis of unknown etiology.
Long-term clinical and histopathological follow-up of chronic posttransfusion
With approval from our institutional review board, whole blood samples were collected from: (1) patients with transfusion reactions, but without signs of hypotension posttransfusion
(n = 4; randomly selected controls) and (2) patients with reported reactions fitting the criteria of classic acute hypotensive transfusion reactions, but not taking ACE-Is prior to, or at the time of, the reaction (n = 4).
Testing of posttransfusion
samples can produce false-positive and false-negative test results, and cannot be relied upon for newborn screening or other definitive laboratory diagnostics.
Seronegative recipients who had received seropositive blood were retested 30 days posttransfusion
to identify seroconversions.
Prospective controlled study of posttransfusion
hepatitis after cardiac surgery in a large referral hospital in India.
It is recommended that transfusion should be carried out with phenotypically matched, leuko-reduced, sickle-cell-negative blood in order to attain a posttransfusion
hematocrit of about 36%.
A 57-study metaanalysis found that the rate of progression to cirrhosis at 20 years was estimated to be 22% in cross-sectional series of people referred to liver specialty clinics with posttransfusion
hepatitis, 24% in longitudinal studies of people with posttransfusion
hepatitis, 4% in cross-sectional series of people newly diagnosed with chronic hepatitis C virus infection at blood-donor screening, and about 6% in community-based studies (Hepatology 34[4 Pr.
A reverse-transcription polymerase chain reaction (PCR) assay demonstrated this virus in patients with non-ABC posttransfusion
The recipients of the 1992 Karl Landsteiner Memorial Award were honored for recognizing the clinical implications of posttransfusion
non-A, non-B hepatitis, physiochemically characterizing an agent not yet visualized, developing a novel approach to the molecular cloning and characterization of the genome of the causative agents, the hepatitis C virus, and expressing virus-specific proteins that formed the basis for the first hepatitis C antibody test.
We allowed a maximum of 7 days between the first and last transfusions for patients who received multiple transfusions; therefore, the maximum time between the pre- and posttransfusion
Babesiosis, although difficult to diagnose, needs to be diagnosed for various reasons: 1) without treatment, babesiosis can lead to severe illness; 2) the disease can persist for a long period without symptoms, which could lead to posttransfusion
cases (12); and 3) effective specific treatments are available (atovaquone plus azithromycin, or for severe cases, clindamycin and quinine) (2).